[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658791":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":16,"studyPopulation":17,"armGroups":11,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":32,"responsibleParty":49,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":11,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":11,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Lymphedema Life Impact Scale (LLIS) questionnaire",null,"Through study completion; an average of 1 year.",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","Primary Objectives The primary objective is to reliably describe risk factors for development of BCRL in IBC using BIA.","UT MD Anderson Cancer Center",[19],{"type":20,"name":21,"description":22,"armGroupLabels":11,"otherNames":11},"DRUG","Neoadjuvant therapy","all patients will start\u002Fcontinue neoadjuvant systemic therapy",[24],{"name":25,"affiliation":17,"role":26},"Anthony Lucci, MD","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":11,"email":31},"CONTACT","713-563-1871","ALucci@mdanderson.org",[33],{"facility":17,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Houston","Texas","77030","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-95.36327,29.76328,{"lat":44,"lon":43},[47,48],{"name":25,"role":29,"phone":30,"phoneExt":11,"email":31},{"name":25,"role":26,"phone":11,"phoneExt":11,"email":11},{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100658791","prediction-of-lymphedema-in-patients-with-inflammatory-breastcancer-using-preoperative-bioimpedance-measurements-100658791",false,"NCT07855627","Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements","Eligibility Criteria All women≥18 years old with newly diagnosed inflammatory breast cancer without prior breast\u002Faxillary surgery who are eligible for standard of care (NST, MRM, and radiation therapy).\n\nExclusion Criteria Prior breast\u002Faxillary surgery. Participants with pacemakers or other implanted electronic medical devices. Participants with implanted metallic material. All vulnerable populations, including children, pregnant women, and cognitively impaired adult","FEMALE","18 Years",{"count":60,"type":61},150,"ESTIMATED","OBSERVATIONAL","To find out whether the BIA test can help identify participants with IBC who are at risk for developing lymphedema.",[65,66,67,68],"Lymphedema","Inflammatory Breast Cancer (IBC)","Preoperative","Bioimpedance Measurement","2026-09-29",{"date":71,"type":72},"2026-10-02","ACTUAL",{"date":74,"type":72},"2026-09-16",{"date":76,"type":61},"2029-12-31",{"name":5,"class":6},1]